Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded in 1993 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2012
Exchange: NASDAQ
Website: merrimack.com
| Date | Price Target | Rating | Analyst |
|---|
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua
Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its stockholders, subject to receipt of stockholder approval of the Plan of Dissolution. The Company currently estimates a cash divid
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023. "As Ipsen reported in February, the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC)," said Gary Crocker, CEO and Chairman of Merrimack's Board of Directors. "This approval triggers a $225 million payment which is due from Ipsen to Merrimack before the end of March. We expect to hold a
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65 and $15.35 per Share in the Late Spring or Early Summer Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and o
15-12G - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
10-Q - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
25 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
8-K - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
DEFA14A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
8-K - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
DEFA14A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
8-K - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
DEFR14A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
DEFA14A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Filer)
STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share. The dividend is expected to be paid on or about May 17, 2024. Merrimack's Common Stock will trade on NASDAQ through May 17, 2024 and will delist from NASDAQ on May 20, 2024. "We appreciate shareholder support for the plan of dissolution and the opportunity to fulfill our commitment to return milestone proceeds to the shareholders" said Gary Crocker, CEO and Chairman of Merr
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that the Board of Directors intends to declare a liquidating cash dividend in the amount of $15.10 per share, if stockholder approval of the Plan of Dissolution is obtained at the Special Meeting of Stockholders held on May 10, 2024. The dividend is expected to be paid on or about May 17, 2024, to stockholders of record on May 10, 2024. We cannot predict with certainty the amount of liquidating distributions to our stockholders. Based on the information currently available to us, we estimate that the aggregate amount initially to be distributed to stockholders will be $15.10 per share. Total actua
Company Updates Potential Range of Initial Liquidating Distribution and Additional Dividend Information Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced that it has filed notice with NASDAQ of the Company's intent to delist its securities from NASDAQ, subject to receipt of stockholder approval of the Plan of Dissolution at the Special Meeting of Stockholders of Merrimack scheduled to be held on Friday, May 10, 2024. Under the Plan of Dissolution, Merrimack intends to issue an initial liquidating cash dividend to its stockholders, subject to receipt of stockholder approval of the Plan of Dissolution. The Company currently estimates a cash divid
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2023 financial results for the period ended December 31, 2023. "As Ipsen reported in February, the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) as a first-line treatment for people living with metastatic pancreatic ductal adenocarcinoma (mPDAC)," said Gary Crocker, CEO and Chairman of Merrimack's Board of Directors. "This approval triggers a $225 million payment which is due from Ipsen to Merrimack before the end of March. We expect to hold a
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65 and $15.35 per Share in the Late Spring or Early Summer Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") reported that Ipsen, SA ("Ipsen") issued a press release today announcing the U.S. Food and Drug Administration has approved the supplemental new drug application for Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and o
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its third quarter 2023 financial results for the period ended September 30, 2023. "During the third quarter we saw interest income on our cash and short term investments offset a significant portion of our operating expenses" said Gary Crocker, Chairman of Merrimack's Board of Directors. "We continue to monitor developments in Ipsen's Onivyde® (irinotecan liposomal injection) program and Elevation's seribantumab program." Third Quarter 2023 Financial Results Merrimack reported a net loss of $279 thousand for the third quarter ended September 30, 2023, or $0.02 per basic and diluted share on
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its second quarter 2023 financial results for the period ended June 30, 2023. "We were excited to see the announcement from Ipsen that the U.S. Food and Drug Administration (FDA) had accepted its supplemental new drug application (sNDA) Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC) and that the FDA had provided a Prescription Drug User Fee Act goal date of 13 February 2024 for review of the application" said Gary Crocker, Chairman of Merrimack'
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [("Merrimack" or the "Company")] today announced its first quarter 2023 financial results for the period ended March 31, 2023. "During the first quarter of 2023 our operating expenses remained consistent with prior quarters and were reduced both by proceeds we received from the receipt of an option fee paid in connection with the entry into an asset purchase option agreement on a preclinical asset and increased interest income" said Gary Crocker, Chairman of Merrimack's Board of Directors. "We continue to be focused on maintaining cash balances that will allow us to be in a position to receive potential milestone payments from Ipsen and Elevat
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022. "We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in November 2022 and the guidance that Ipsen has subsequently provided regarding its intention to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde® in previously untreated patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"), which could lead to a potential future milestone payment from Ipsen" said Gary Crocker, CEO and Chairman of Merrimack's Board of Directors. "As a result of the exe
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
4 - MERRIMACK PHARMACEUTICALS INC (0001274792) (Issuer)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13D/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)
SC 13G/A - MERRIMACK PHARMACEUTICALS INC (0001274792) (Subject)